Splenopentin & Immunofan: Russian Immune Peptides

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/splenopentin-immunofan-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider, especially for immune-modulating peptides with autoimmune or oncologic considerations.

Overview

Splenopentin and Immunofan (also spelled Imunofan) are two Russian-developed immunomodulatory peptides used extensively in clinical practice across Russia and CIS countries for immunodeficiency, chronic viral infection, and as adjuncts to oncologic therapy. Both sit outside the FDA-approved framework and are largely unknown to Western practitioners, but they have a substantial domestic clinical literature.

Splenopentin is a pentapeptide with the sequence Arg-Lys-Glu-Val-Tyr, derived from research into Splenin (a splenic-origin immunoregulatory fraction) and structurally related to the tuftsin family of phagocyte-activating peptides. It is one of the shorter, less internationally studied members of the Russian immunopeptide tradition.

Immunofan / Imunofan is a synthetic hexapeptide with the sequence Arg-α-Asp-Lys-Val-Tyr-Arg, designed in the 1990s to deliver a multi-phase immune modulation profile in a single molecule. It is approved as a pharmaceutical in Russia and is prescribed for chronic infections, post-surgical immunity, burn recovery, and as adjuvant therapy during chemotherapy.

Both peptides emerged from the Russian immunopharmacology tradition associated with researchers such as Lebedev, Karaulov, and the Khavinson school. The international evidence base is limited, but the Russian clinical record spans decades.

Mechanism of Action — Splenopentin

Splenopentin is functionally classified within the tuftsin family of immunoregulatory peptides. Tuftsin itself (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide cleaved from the Fc region of IgG that activates phagocytes. Splenopentin shares overlapping biological territory while having a distinct sequence and origin.

Proposed mechanisms include:

1. Phagocyte stimulation — enhanced neutrophil and macrophage chemotaxis and phagocytic activity
2. T-cell maturation support — promotes maturation of T-precursor cells into functional CD4+ and CD8+ populations
3. NK cell activity modulation — modest enhancement reported in Russian in vitro work
4. Cytokine balance — gentle nudging of Th1/Th2 ratios rather than aggressive polarization
5. Splenic-axis signaling — historically derived from splenin fractions, implicating splenic-origin immunoregulation

Splenopentin is markedly less studied than Immunofan or Thymosin Alpha-1, and most of the available literature is in Russian-language immunology journals from the 1980s through early 2000s. It is best understood as a gentle, broad immunostimulant rather than a phase-specific modulator.

Mechanism of Action — Immunofan

Immunofan was specifically designed for a three-phase sequential action profile that maps onto the natural arc of immune recovery. This phase coverage is what distinguishes it from most single-mechanism immune peptides.

Phase 1 — Acute (Days 1-3): Antioxidant & Detoxification

• Upregulation of ceruloplasmin and lactoferrin
• Restoration of antioxidant enzyme activity (SOD, catalase)
• Reduction of lipid peroxidation markers
• Useful in oxidative stress states (chemotherapy, burns, sepsis recovery)

Phase 2 — Medium (Days 4-7): Cytokine Normalization

• Th1/Th2 balance restoration
• Normalization of TNF-α, IL-1, IL-6 in dysregulated states
• Modulation of IgE in allergic dysregulation
• Restoration of complement system function

Phase 3 — Late (Days 7-21): Cell-Mediated Immunity Restoration

• T-cell population recovery (CD3+, CD4+, CD8+)
• Improved CD4/CD8 ratio in chronically suppressed patients
• Enhanced antibody response to recall antigens
• NK cell functional restoration

This sequenced profile is why Russian protocols commonly use Immunofan as a 5-10 day course rather than continuous daily dosing — the molecule is engineered to walk the immune system through recovery phases.

Russian Clinical Indications

Immunofan is approved and prescribed in Russia for an extensive list of indications. Splenopentin overlaps but is more niche. Key clinical uses include:

• Chronic viral infections — Hepatitis B and C (as adjunct to antivirals), HIV (immune support adjunct, not antiretroviral)
• Oncology adjuvant therapy — given during and after chemotherapy/radiation to support hematopoietic and immune recovery; also used post-surgically in cancer patients
• Post-burn and post-trauma immunity — major burn centers in Russia incorporate Immunofan into recovery protocols
• Recurrent respiratory and urogenital infections — patients with frequent infection cycles unresponsive to standard care
• Opportunistic infections — secondary immunodeficiency from chronic illness
• Sepsis recovery — adjunct in ICU protocols for post-sepsis immunoparalysis
• Pediatric infections — Russian pediatric pulmonology uses Immunofan for chronic and recurrent presentations

Splenopentin is used in similar contexts, particularly secondary immunodeficiency, but is less standardized in Russian formularies.

Dosing Protocols

Both peptides are designed for short, intensive courses rather than continuous use. The Russian clinical pattern is course-based dosing, repeated as needed.

Reconstitution typically uses bacteriostatic water; both peptides require refrigeration after reconstitution. Intranasal Immunofan is a finished pharmaceutical product in Russia (commercial spray formulation) and is preferred for pediatric or needle-averse use cases.

Immunofan vs Thymosin Alpha-1 vs Thymulin

These three peptides are the most commonly compared immune modulators in the thymic and related families.

The takeaway: if the goal is oncologic adjunct support or sequential phase-based recovery, Immunofan has a unique design profile. For chronic viral or general immune optimization in a US/international context, Thymosin Alpha-1 has a more accessible evidence base and supply chain.

Expected Outcomes

Outcomes are most pronounced in patients who are immunologically compromised at baseline. Healthy individuals using these peptides for "optimization" typically see subtle or no measurable changes.

Week 1:

• Subjective energy and recovery improvements in chronically ill patients
• Reduced symptom burden in recurrent infection cycles
• Antioxidant marker normalization (Immunofan acute phase)

Week 2-3:

• T-cell count shifts (CD4+, CD8+) toward normal ranges in immunosuppressed patients
• NK cell activity uptick in dysregulated baselines
• Improved CD4/CD8 ratio in chronic infection contexts

Beyond 3 weeks (or with repeated courses):

• Reduced infection frequency over subsequent months
• Improved tolerance of chemotherapy cycles (oncology adjunct context)
• Faster recovery from acute infections

These effects are far more reliably reported in immunocompromised populations than in healthy biohackers. The signal-to-noise in healthy people is low.

Side Effects & Safety

Russian clinical trials consistently report excellent tolerability across thousands of patient-course exposures. Reported issues:

• Injection site reactions — mild redness, transient
• Allergic reactions — uncommon but documented (rash, urticaria); rare anaphylactoid responses
• Mild fatigue or flu-like sensation — first 1-2 days, typically resolves
• Theoretical Th1 enhancement risk — as with all thymic-class and related immunopeptides, there is a theoretical concern about provoking flares in Hashimoto's thyroiditis, rheumatoid arthritis, multiple sclerosis, lupus, psoriasis, or other Th1-driven autoimmune conditions

Contraindications:

• Active autoimmune disease (relative contraindication — practitioner judgment required)
• Pregnancy and breastfeeding (not studied)
• Pediatric use only under specialist supervision (note: Russian pediatric protocols exist)
• Known peptide allergy

Stacking

Immune peptide stacks should be designed conservatively. Combining multiple immunostimulants can amplify both benefit and autoimmune risk.

Immunofan + Thymosin Alpha-1 Broader immune coverage by combining Immunofan's multi-phase profile with Tα1's chronic viral and T-cell support. Use sequentially (Immunofan course, then Tα1 maintenance) rather than simultaneously to avoid stacking immune activation signals.

Splenopentin + Immunofan Russian practitioners occasionally combine these or use them sequentially — Splenopentin's phagocyte stimulation paired with Immunofan's phase coverage. Limited international protocols exist.

Khavinson Bioregulator Stack (Thymalin / Thymogen) Pairing Immunofan with Thymalin or Thymogen aligns with the broader Russian immunopeptide tradition. Use as alternating short courses rather than concurrent stacking.

Avoid:

• Concurrent stacking with potent Th1-shifting agents in autoimmune patients
• Combining with TNF-α modulators without medical supervision

Cycling

The Russian clinical model is course-based, not continuous:

• Standard intensive course: 5-10 days of daily dosing
• Repeat interval: Every 3-6 months as clinically indicated
• Oncology adjunct cycling: Aligned with chemotherapy cycles per protocol
• Maintenance variant: Lower-frequency dosing (e.g., every 2-3 days) for 2-3 week extended periods in chronic indications
• Long continuous use: Possible at reduced frequency but uncommon in published protocols

Cycling matters more for these peptides than for many others because the multi-phase action of Immunofan is engineered around a 21-day arc. Continuous daily dosing beyond that window may not add benefit.

Sourcing Considerations

Authentic sourcing is the most significant practical barrier for US-based users.

• Immunofan is a registered Russian pharmaceutical (ampoules and intranasal spray) — authentic product flows through the Russian/CIS pharmacy system
• Importing finished Russian pharmaceuticals to the US is legally and logistically complicated
• The research chemical market includes a significant counterfeit fraction for both peptides — sequences sold as "Immunofan" or "Splenopentin" may be mislabeled or impure
• US compounding pharmacy access is uncommon — most US compounders do not carry these
• Third-party COAs are essential but not sufficient; mass spectrometry confirming the correct sequence is the gold standard
• Price anomalies (unusually cheap) are a red flag for counterfeit material

If you are considering these peptides, work with a practitioner familiar with the Russian immunopeptide literature and demand sequence-confirmed COAs. Buying blindly from research chemical sites carries meaningful risk of receiving the wrong molecule entirely.

Frequently Asked Questions

Q: Is Immunofan actually effective for chronic illness? A: The Russian clinical evidence base supports use in chronic viral infections, post-trauma recovery, and oncologic adjuvant settings. International validation is limited. The strongest signals are in immunocompromised populations, not healthy users.

Q: Can I stack Immunofan with Thymosin Alpha-1? A: They are often used sequentially rather than simultaneously. Stacking is plausible under practitioner guidance but compounds the theoretical autoimmune risk and isn't well documented in protocols.

Q: Is Immunofan safe as a cancer adjuvant? A: It is used this way routinely in Russia, including during chemotherapy. In a US context, this requires oncology team involvement — not a self-directed decision.

Q: What is the autoimmune flare risk? A: Theoretical, not well-quantified. As with all thymic-class and immunostimulatory peptides, caution is warranted in Hashimoto's, RA, MS, lupus, and psoriasis. Most Russian protocols screen for active autoimmunity before use.

Q: How do I find authentic Immunofan or Splenopentin? A: This is the hardest practical question. Authentic Russian pharmaceutical Immunofan rarely reaches US users. Research chemical sources require sequence-confirmed COAs. Work with a practitioner familiar with Russian immunopeptides if possible.

Q: Can Immunofan help with long COVID? A: Anecdotal interest exists given its post-viral and immune-restoration profile, but there is no published controlled data on long COVID specifically. This is an off-label, experimental use.

Q: Is intranasal Immunofan as effective as injectable? A: Russian commercial intranasal spray is widely used, particularly in pediatric and recurrent respiratory infection contexts. Bioavailability differs from injection, but clinical outcomes for ENT and respiratory indications are reported as comparable.

Q: How long until I see results? A: Subjective changes can appear in week one. Measurable immune marker shifts typically require 2-3 weeks or a full course. Healthy users may notice nothing.

Related Content

• Thymosin Alpha-1 Protocol
• Thymulin Protocol
• Khavinson Bioregulator Stack
• Immune Peptide Comparison
• Sourcing & COA Reading Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Splenopentin and Immunofan are not FDA-approved for human use in the United States. Immunofan is approved as a pharmaceutical in Russia and CIS countries. Consult a licensed healthcare provider before considering immune-modulating peptides, especially with any history of autoimmune disease, active malignancy, or chronic infection.

Source: https://peptides.nyc/learn/splenopentin-immunofan-protocol